Table 1. Expression of immuno-staining and mismatch repair status of 11 primary leiomyosarcomas associated with patient survival.
| # | Diagnosis | Survival | MMR status | PDL-1 intensity | PDL-1 % positive cells |
PD-1 T intensity | PD-1 P intensity | CD3 T intensity | CD3 P intensity | CD8 T intensity | CD8 P intensity |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1* | LMS extremity | 38 m | PMS2 deficient |
0 | 0% | 1 | 2 | 1 | 2 | 1 | 1 |
| 2 | ULMS | 31 m | Proficient | 0 | 0% | 0 | 0 | 1 | 1 | 2 | 2 |
| 3 | LMS extremity |
28 m | Proficient | 1 | 20% | 1 | NA | 1 | NA | 1 | NA |
| 4 | ULMS | 28 m | Proficient | 0 | 0% | 1 | 0 | 1 | NA | 1 | NA |
| 5 | LMS testis |
23 m | Proficient | 3 | 1% | 0 | 1 | 3 | 1 | 2 | 1 |
| 6 | ULMS | 15 m | Proficient | 3 | 5% | 2 | 2 | 1 | 1 | 2 | 1 |
| 7 | LMS retroperitoneum |
4 m | Proficient | 3 | 5% | 3 | 1 | 3 | 3 | 3 | 3 |
| 8 | ULMS | Alive | Proficient | 0 | 0% | 3 | 3 | 3 | 3 | 1 | 0 |
| 9 | LMS dermis |
Alive | Proficient | 0 | 0% | 0 | 0 | 1 | 1 | 0 | 0 |
| 10 | ULMS | Alive (Recurrence free) |
Proficient | 0 | 0% | 0 | 0 | 3 | 3 | 2 | 3 |
| 11* | ULMS | Alive (Recurrence free) |
PMS2 deficient |
0 | 0% | 0 | 0 | 2 | 2 | 1 | 1 |
Abbreviations: LMS, leiomyosarcoma, ULMS, uterine Leiomyosarcoma, PD-L1, programmed cell death ligand 1, PD-1, programmed cell death 1, T, tumor, P, tumor periphery. *patients with MMR-D sarcomas.